Cargando…
NMNAT3 is protective against the effects of neonatal cerebral hypoxia‐ischemia
OBJECTIVE: To determine whether the NAD+ biosynthetic protein, nicotinamide mononucleotide adenylyltransferase‐3 (NMNAT3), is a neuroprotective inducible enzyme capable of decreasing cerebral injury after neonatal hypoxia‐ischemia (H‐I) and reducing glutamate receptor‐mediated excitotoxic neurodegen...
Autores principales: | Galindo, Rafael, Banks Greenberg, Marianne, Araki, Toshiyuki, Sasaki, Yo, Mehta, Nehali, Milbrandt, Jeffrey, Holtzman, David M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5634348/ https://www.ncbi.nlm.nih.gov/pubmed/29046881 http://dx.doi.org/10.1002/acn3.450 |
Ejemplares similares
-
NMNAT1 inhibits axon degeneration via blockade of SARM1-mediated NAD(+) depletion
por: Sasaki, Yo, et al.
Publicado: (2016) -
Nmnat1 protects neuronal function without altering phospho‐tau pathology in a mouse model of tauopathy
por: Musiek, Erik S., et al.
Publicado: (2016) -
MAPK signaling promotes axonal degeneration by speeding the turnover of the axonal maintenance factor NMNAT2
por: Walker, Lauren J, et al.
Publicado: (2017) -
SARM1 depletion rescues NMNAT1-dependent photoreceptor cell death and retinal degeneration
por: Sasaki, Yo, et al.
Publicado: (2020) -
Pretreatment with Human Chorionic Gonadotropin Protects the Neonatal Brain against the Effects of Hypoxic-Ischemic Injury
por: Movsas, Tammy Z., et al.
Publicado: (2017)